Anzeige
Mehr »
Dienstag, 28.10.2025 - Börsentäglich über 12.000 News
Atomkraft feiert Comeback: Uran wird wieder zum strategischen Rohstoff - Anleger stehen Schlange
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BED | ISIN: SE0024173637 | Ticker-Symbol: 7AL0
Frankfurt
28.10.25 | 08:01
0,091 Euro
-18,12 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALLIGATOR BIOSCIENCE AB Chart 1 Jahr
5-Tage-Chart
ALLIGATOR BIOSCIENCE AB 5-Tage-Chart

Aktuelle News zur ALLIGATOR BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAlligator Bioscience AB GAAP EPS of -SEK 0.34, revenue of SEK 0.47M3
DoAlligator Bioscience AB Reports Financial Results for Q3 2025 and Provides a Business Update207Upcoming rights issue of approx. SEK 120 million (gross), providing 6-9 months of financial runway during 2026, announced 22 OctoberSuccessful warrant program TO 13 raises SEK 28.1 million (gross)Final...
► Artikel lesen
DoNotice of Extraordinary General Meeting in Alligator Bioscience AB275LUND, SE / ACCESS Newswire / October 22, 2025 / Alligator Bioscience (STO:ATORX)The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation...
► Artikel lesen
ALLIGATOR BIOSCIENCE Aktie jetzt für 0€ handeln
MiAlligator Bioscience Carries Out a Rights Issue of Units of Approximately SEK 120 Million and Raises Bridge Loans285NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA...
► Artikel lesen
21.10.Alligator Bioscience Granted US Patent Covering ATOR-4066 Bispecific Antibody209LUND, SE / ACCESS Newswire / October 21, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs...
► Artikel lesen
16.10.Invitation to Alligator Bioscience's Earnings Call on 23 October 2025172LUND, SE / ACCESS Newswire / October 16, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) ), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody...
► Artikel lesen
13.10.Alligator Bioscience: REACtiVe-2 Phase 1 Data Featuring Mitazalimab Demonstrate Immune Activation in Metastatic Pancreatic Cancer - To be Presented at ESMO 2025217LUND, SE / ACCESS Newswire / October 13, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs...
► Artikel lesen
08.10.Alligator Bioscience: Alligator Announces Publication of OPTIMIZE-1 Biomarker Analysis in Cell Reports Medicine Supporting mitazalimab and mFOLFIRINOX in Metastatic Pancreatic Cancer176LUND, SE / ACCESS Newswire / October 8, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs...
► Artikel lesen
06.10.Alligator Bioscience Announces Acceptance of Two Abstracts at SITC 40th Anniversary Annual Meeting171LUND, SWEDEN / ACCESS Newswire / October 6, 2025 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced...
► Artikel lesen
22.09.Alligator Bioscience: Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer220LUND, SE / ACCESS Newswire / September 22, 2025 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody...
► Artikel lesen
17.09.Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 13258LUND, SWEDEN / ACCESS Newswire / September 17, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS...
► Artikel lesen
16.09.Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 13263LUND, SE / ACCESS Newswire / September 16, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS...
► Artikel lesen
12.09.Alligator Bioscience: Alligator to Present New Preclinical Results on ATOR-4066 at CICON25306LUND, SE / ACCESS Newswire / September 12, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, announced...
► Artikel lesen
11.09.Last Day of Trading in Warrants Series TO 13 in Alligator Bioscience is 11 September 2025282LUND, SE / ACCESS Newswire / September 11, 2025 / Alligator Bioscience (STO:ATORX)NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA...
► Artikel lesen
10.09.Alligator Bioscience: Alligator Announces Publication in Cancer Immunology Research of Preclinical Data on ATOR-4066, a Tumor-Directed CD40×CEACAM5 Bispecific Antibody280LUND, SE / ACCESS Newswire / September 10, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today...
► Artikel lesen
09.09.Alligator Bioscience Has Renegotiated the Outstanding Loan From Fenja Capital and Received Subscription Intentions From Members of the Board of Directors and Management380NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH...
► Artikel lesen
08.09.Alligator Bioscience: Grant Awarded to Investigator-Initiated Phase 2/3 Trial with Mitazalimab in Biliary Tract Cancer300LUND, SE / ACCESS Newswire / September 8, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today...
► Artikel lesen
05.09.Alligator Bioscience to present at BioStock's "Investing in Life Science" event262LUND, SE / ACCESS Newswire / September 5, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today...
► Artikel lesen
02.09.Alligator Bioscience: Alligator Announces Evaluation and Option Agreement Covering RUBY Antibody Format286LUND, SWEDEN / ACCESS Newswire / September 2, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Alligator has entered into an evaluation and option agreement with an infectious...
► Artikel lesen
27.08.Exercise Price Determined for the Exercise of Warrants Series TO 13 in Alligator Bioscience AB330NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA...
► Artikel lesen
Weiter >>
90 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4